# DESTINY-Breast05 (NCT04622319)

> A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04622319
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer
- Interventions: DS-8201a; T-DM1
- Enrollment: 1600
- Primary outcome: Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 93
- X threads: 86
- Podcasts: 55
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-breast05-nct04622319

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04622319", "email": "<work email>"}; the inbox owner confirms by the emailed link.